Poynard owns stock in Biopredictive. He also consults for and is on the speakers' bureau of Merck. Dr. Pol consults for, advises, and is on the speakers' bureau of Boehringer Ingleheim, Abbott, and GlaxoSmithKline. He consults for, advises, is on the speakers' bureau of, and received grants from Roc
Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1
✍ Scribed by Tobias Mueller; Reinhard Geßner; Christoph Sarrazin; Carola Graf; Juliane Halangk; Heiko Witt; Eckart Köttgen; Bertram Wiedenmann; Thomas Berg
- Book ID
- 108138168
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 55 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Anemia may increase the likelihood of achieving a sustained virological response (SVR) during pegylated interferon and ribavirin treatment of hepatitis C virus (HCV) infection. To determine whether hemoglobin decline is associated with SVR, we retrospectively evaluated the CHARIOT study of 871 treat
## Abstract Hepatitis C virus (HCV) genotype 1b is the most prevalent in Argentina. As observed in most HCV‐genotype 1b described previously worldwide, the population analyzed in this work is growing at exponential rate. Ten out of 22 samples tested comprise a well‐defined cluster. This new cluster
## Abstract Heterogeneity of subgenomic regions of hepatitis C virus (HCV) may be associated with response to interferon (IFN) therapy. The amino acid sequences of the PKR/eIF‐2α phosphorylation homology domain (pePHD), IFN sensitivity determining region (ISDR), PKR binding domain (PKRBD), and vari